<DOC>
	<DOCNO>NCT00593385</DOCNO>
	<brief_summary>Prospective , multicenter , non-randomized , single-arm registry evaluate safety effectiveness iCAST Covered Stent System treatment patient symptomatic claudication rest pain angiographic confirmation de novo restenotic lesion common and/or external iliac artery .</brief_summary>
	<brief_title>Atrium iCAST Iliac Stent Pivotal Study</brief_title>
	<detailed_description>STUDY DESIGN : Prospective , multicenter , non-randomized , single-arm registry OBJECTIVE : The primary objective evaluate iCAST cover stent performance metric derive study FDA-approved iliac stent device treat iliac artery stenoses patient de novo restenotic lesion common and/or external iliac artery . NUMBER OF SUBJECTS : 165 subject , include 25 subject totally occluded lesion . PRIMARY ENDPOINTS : The primary endpoint composite endpoint define occurrence death within 30 day , target site revascularization restenosis ( ultrasound determination ) within 9 month post-procedure . SECONDARY ENDPOINTS : Secondary endpoint include : 1 . Major adverse vascular event ( MAVE ) define composite rate myocardial infarction 30 day , stent thrombosis , clinically apparent distal embolization , define cause end-organ damage ( e.g . low extremity ulceration , tissue necrosis , gangrene ) , arterial rupture , acute limb ischemia , target limb amputation procedure relate bleeding event require transfusion . 2 . A major adverse event ( MAE ) define composite rate MAVE death , stroke , 30 day post-procedure . 3 . Device success , define successful delivery deployment study stent intact retrieval delivery system . 4 . Acute procedural success , define device success achievement &lt; 30 % residual stenosis immediately stent deployment , mean transtenotic pressure gradient &lt; 5 mmHg without occurrence in-hospital MAVE . 5 . Clinical success , assess early ( 30 day ) late ( 6 , 9 12 month ) . 6 . Patency assess follow-up time point , categorize primary , primary-assisted secondary patency . 7 . Composite rate 30 day death , 9 month target site revascularization 9 month restenosis subject without iliac total occlusion . PATIENT POPULATION : Eligible patient symptomatic claudication rest pain angiographic confirmation either de novo restenotic lesion common and/or external iliac artery .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Subject 18 year age old . 2 . Subject lifestyle limit claudication rest pain ( RutherfordBecker scale 24 ) . 3 . Presence de novo and/or restenotic lesion common and/or external iliac artery . 4 . Subject single , bilateral multiple target lesion ( ) ≥ 50 % stenosed visual estimate . 5 . The target lesion ( ) successfully cross guide wire dilate . 6 . The target segment subject 's lesion ( ) 5 12mm diameter less 110 mm length . 7 . Subject angiographic evidence patent profunda superficial femoral artery ( SFA ) target limb . 8 . Subject provide write informed consent . 9 . Subject able willing adhere require followup visit test month 36 . 10 . Subject able willing adhere require followup medication regimen . 1 . Presence nontarget ipsilateral arterial lesion require treatment within 30 day postprocedure ( Note treatment ipsilateral SFA lesion may allow certain circumstance ) . Treatment lesion vascular bed must complete least 30 day prior enrollment . 2 . The target lesion ( ) adjacent , acute thrombus . 3 . The target lesion ( ) highly calcify previously treat stent . 4 . Target lesion involves internal iliac artery result cross sidebranch iCAST device ( e.g . `` jail '' sidebranch ) . 5 . Subject abdominal aortic aneurysm contiguous iliac artery target lesion . 6 . Subject preexist target iliac artery aneurysm perforation dissection target iliac artery prior initiation iCAST implant procedure . 7 . Subject postsurgical stenosis anastomotic suture treatment target vessel . 8 . Subject vascular graft previously implant native iliac vessel . 9 . Subject tissue loss , define RutherfordBecker classification category 5 6 . 10 . Subject contrast agent hypersensitivity adequately premedicated , hypersensitivity stainless steel , expand polytetrafluoroethylene ( ePTFE ) intolerance antiplatelet , anticoagulant , thrombolytic medication . 11 . History neutropenia ( WBC &lt; 3,000/mm3 ) , coagulopathy , thrombocytopenia ( platelet count &lt; 80,000/ μL ) resolve require treatment past 6 month . 12 . Known bleed hypercoagulability disorder significant anemia ( Hb &lt; 8.0 ) correct . 13 . Subject follow laboratory value : 1. platelet count le 80,000/ μL , 2. prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit 3. serum creatinine level great 2.5 mg/dL 14 . Subject require general anesthesia procedure . 15 . Subject pregnant . 16 . Subject comorbid illness may result life expectancy le 1 year . 17 . Subject participate investigational study new drug , biologic device time study screen . NOTE : Subjects participate long term followup phase previously investigational FDAapproved product exclude criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Symptomatic claudication rest pain angiographic confirmation either de novo restenotic lesion common and/or external iliac artery .</keyword>
</DOC>